SCHEMBL4831429

SCHEMBL4831429

COc1cccc(C(=O)Nc2ccc(N3CN=c4sccc4=C3N)cc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 7/20 0.57
▸ MAPT P10636 7/20 0.57
▸ NPC1 O15118 6/20 0.57
▸ RAB9A P51151 5/20 0.57
▸ ALDH1A1 P00352 5/20 0.57
▸ LMNA P02545 4/20 0.57
▸ PKM P14618 2/20 0.57
▸ QSOX1 O00391 1/20 0.57
▸ GAA P10253 1/20 0.52
▸ TP53 P04637 3/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ TSHR P16473 1/20 0.50
▸ NFKB1 P19838 1/20 0.50
▸ NFKB2 Q00653 1/20 0.50
▸ RELA Q04206 1/20 0.50
▸ F10 P00742 1/20 0.49
▸ KMT2A Q03164 6/20 0.49
▸ MEN1 O00255 4/20 0.49
▸ HPGD P15428 1/20 0.49
▸ MAPK1 P28482 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4826276 0.86 RAB9A (0.54) SMN1; SMN2MAPTNPC1RAB9AALDH1A1
SCHEMBL4835290 0.85 RAB9A (0.49) SMN1; SMN2MAPTNPC1RAB9ALMNA
SCHEMBL4833666 0.85 L3MBTL1 (0.47) SMN1; SMN2MAPTNPC1RAB9AALDH1A1
SCHEMBL4833891 0.81 MAPT (0.54) SMN1; SMN2MAPTNPC1RAB9AALDH1A1
SCHEMBL4831024 0.79 TRPV1 (0.50) SMN1; SMN2MAPTNPC1TSHRKMT2A
SCHEMBL4825807 0.77 PKM (0.46) SMN1; SMN2MAPTNPC1RAB9AALDH1A1
SCHEMBL4831551 0.75 LCK (0.50) MAPTRAB9AALDH1A1PKMKDM4E
SCHEMBL4826345 0.75 NPC1 (0.37) SMN1; SMN2MAPTNPC1RAB9AALDH1A1
SCHEMBL4828766 0.75 RAB9A (0.47) SMN1; SMN2MAPTNPC1RAB9ALMNA
SCHEMBL4835951 0.74 LMNA (0.44) SMN1; SMN2MAPTALDH1A1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP claimed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK SMN1; SMN2 4268/4885MAPT 2499/4885NPC1 4117/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR SMN1; SMN2 3836/4885MAPT 2424/4885NPC1 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback